期刊
NEUROPHARMACOLOGY
卷 75, 期 -, 页码 145-154出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2013.07.022
关键词
Abuse liability; Delta-9-tetrahydrocannabinol; Drug discrimination; Synthetic cannabinoids; UR-144; XLR-11
资金
- Drug Enforcement Agency (DEA)
- NIH/NIDA [DA-031988, DA-03672]
- National Institute of Justice, Office of Justice Programs, U.S. Department of Justice [2012-R2-CX-K001]
Synthetic indole-derived cannabinoids have become commonly used recreational drugs and continue to be abused despite their adverse consequences. As compounds that were identified early in the epidemic (e.g., naphthoylindoles) have become legally banned, new compounds have appeared on the drug market. Two tetramethylcyclopropyl ketone indoles, UR-144 [(1-pentyl-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone] and XLR-11 [(1-(5-fluoropentyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone], recently have been identified in confiscated products. These compounds are structurally related to a series of CB2-selective compounds explored by Abbott Labs. The purpose of the present study was to evaluate the extent to which UR-144 and XLR-11 shared cannabinoid effects with Delta(9)-tetrahydrocannabinol (Delta(9)-THC). Indices of in vitro and in vivo activity at cannabinoid receptors were assessed. Similar to other psychoactive cannabinoid agonists, XLR-11 and UR-144 showed low nanomolar (<30) affinity for CB1 and CB2 receptors, activated these receptors as full agonists, and produced dose-dependent effects that were blocked by rimonabant in mice, including antinociception, hypothermia,.catalepsy and suppression of locomotor activity. The potency of both compounds was several-fold greater than Delta(9)-THC. XLR-11 and UR-144 also substituted for Delta(9)-THC in a Delta(9)-THC discrimination procedure in mice, effects that were attenuated by rimonabant. Analysis of urine from mice treated with the compounds revealed that both were extensively metabolized, with predominant urinary excretion as glucuronide conjugates. Together, these results demonstrate that UR-144 and XLR-11 share a pharmacological profile of in vitro and in vivo effects with Delta(9)-THC and other abused indole-derived cannabinoids and would be predicted to produce Delta(9)-THC-like subjective effects in humans. (C) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据